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Rapid bedside inactivation of Ebola virus would be a solution for the safety of medical and technical staff, risk containment,
sample transport, and high-throughput or rapid diagnostic testing during an outbreak. We show that the commercially available
Magna Pure lysis/binding buffer used for nucleic acid extraction inactivates Ebola virus. A rapid bedside inactivationmethod for
nucleic acid tests is obtained by simply addingMagna Pure lysis/binding buffer directly into vacuum blood collection EDTA
tubes using a thin needle and syringe prior to sampling. The ready-to-use inactivation vacuum tubes are stable for more than 4
months, and Ebola virus RNA is preserved in theMagna Pure lysis/binding buffer for at least 5 weeks independent of the storage
temperature. We also show that Ebola virus RNA can be manually extracted fromMagna Pure lysis/binding buffer-inactivated
samples using the QIAamp viral RNAminikit. We present an easy and convenient method for bedside inactivation using avail-
able blood collection vacuum tubes and reagents. We propose to use this simple method for fast, safe, and easy bedside inactiva-
tion of Ebola virus for safe transport and routine nucleic acid detection.
The most recent Ebola virus disease (EVD) outbreak began inWest Africa in December 2013. As ofMarch 2016, the number
of confirmed, probable, and suspected EVD cases reported world-
wide was 28,646. Guinea, Liberia, and Sierra Leone were the most
affected countries with 3,804, 10,666 and 14,122 cases, respec-
tively (1).
Ebola virus (EBOV) is classified as a risk group 4 pathogen that
requires handling under biosafety level 4 (BSL-4) conditions. To
meet this requirement, several mobile BSL-4 facilities were used
during the recentWest Africa outbreak (1, 2). However, extensive
safety precautions and training of medical and technical staff are
needed to ensure personal safety (2–6). As of August 2015, 880
health care workers had been diagnosed with EVD, and 512 had
died from the disease (7). Rapid bedside inactivation of EBOV
would be a solution for the safety of medical and technical staff,
risk containment, and easier transport of samples without requir-
ing expensive category A shipping. Additionally, this process re-
moves the need for sample handling under high-containment en-
vironments and facilitates high-throughput and rapid testing
under nonbiosafety laboratory conditions and, thus, a rapid diag-
nosis of the disease.
There is a need for a simple, efficient, and safe bedside inacti-
vation method for EBOV. Presently, laboratory EBOV inactiva-
tion is accomplished by gamma irradiation (8), UV radiation (9),
nanoemulsion (10), and photoinducible alkylating agents (11),
but these methods are not applicable in outbreak situations or as
bedside inactivationmethods.Other EBOV inactivationmethods,
such as acetic acid (12), heat (12), AVL buffer (13), TRIzol (13) or
the combination of heat and Triton X-100 (14), are more appli-
cable in outbreak situations and are currently used in field labo-
ratories. Unfortunately, all of these methods require hands-on
handling and manipulation of the sample before EBOV is inacti-
vated.
EVD diagnosis is primarily based on RT-PCR technology (3),
and the current methods for nucleic acid (NA) extraction include
several handling steps with infectious material before EBOV is
inactivated. The steps in the QIAamp viral RNA extraction
method from Qiagen that was used during the recent outbreak
(15) are (i) sample collection; (ii) triple packing systems (5) for the
shipment and transport of samples to high-containment labora-
tories (16); (iii) pipetting of aliquots; (iv) addition of AVL buffer;
(v) incubation; (vi) addition of ethanol; and (vii) disinfection us-
ing 0.5% hypochlorite for 5 min before release from the glove box
(17). These handling steps can be eliminated if efficient bedside
inactivation of EBOV is obtained.
The commercially availableMagna Pure lysis/binding (MPLB)
buffer from Roche was shown to inactivate two species of Or-
thopox virus (Vaccinia virus and Cowpox virus) (18). In this re-
port, we show that MPLB buffer also inactivates EBOV. When
MPLB buffer is directly injected into ordinary vacuum blood col-
lection EDTA tubes using a needle and syringe, a residual vacuum
is maintained, thereby allowing the direct drain of blood from the
patient into the inactivation tube. Thus, a rapid bedside inactiva-
tion method is obtained, and handling of the sample under high-
containment conditions is eliminated. MPLB buffer is produced
for automated Magna Pure NA extraction using a Magna Pure
robot, butwe show that the EBOVRNAcan also be extracted from
MPLB buffer-inactivated blood samples using a slightly modified
version of the manual QIAamp viral RNA minikit. Furthermore,
the EBOVRNA is stable in theMPLBbuffer blood collection tubes
for more than 5 weeks independent of the temperature.
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MATERIALS AND METHODS
EBOV inactivation BSL-4 experiments. All of the EBOV inactivation
experiments were conducted at the BSL-4 laboratory in Stockholm, Swe-
den. EBOV from the recent outbreak (Ebola virus/H.sapiens-tc/SLE/
2014/Makona) was isolated and cultured, and infectivity was quantified
by fluorescence forming units, as previously described (19) (unpublished
data).
Two million cultured infectious EBOV particles corresponding to a
quantification cycle (Cq) value of 15 (data not shown) (100 l) were
mixed 1:1 with MPLB buffer from the Magna Pure LC DNA isolation kit
I (Roche Diagnostics A/S, Risch-Rotkreuz, Switzerland) or mock-treated
with Dulbecco’s modified Eagle medium (DMEM) (Thermo Fisher Sci-
entific, Inc., Waltham, MA, United States). The mixtures were incubated
for 20 min at room temperature and then filtered through the Amicon
100KUltra centrifugal filters according to themanufacturer’s instructions
to wash out the toxic compounds in the MPLB buffer. The filters were
resuspended and diluted 1:500 in DMEM containing 2% fetal bovine
serum (FBS) (Thermo Fisher Scientific, Inc., Waltham, MA, United
States) and 0.01% penicillin-streptomycin (PEST) (Thermo Fisher Scien-
tific, Inc.,Waltham,MA, United States) and added to (3 106 cells) Vero
E6 cells. After 2 h of infection at 37°C, the cells were washed twice and
incubated with DMEM containing 2% FBS and 0.01% PEST. At 24, 48,
144, and 336 h postinfection, the cells were harvested by addition of
TRIzol (Thermo Fisher Scientific, Inc., Waltham, MA, United States) ac-
cording to the manufacturer’s instructions. At 24 and 48 h postinfection,
cells were also fixed with ice-cold methanol-acetone at20°C for 30 min
and processed for immunofluorescence using in-house antibodies target-
ing the EBOV viral matrix protein (VP40) and glycoprotein (GP). Three
independent experiments were performed. In addition, five cultured in-
fectious EBOV particles were mixed 1:1 with MPLB buffer or mock
treatedwithDMEM, filtered, and used to infect Vero E6 cells, as described
above. Three independent experiments were performed.
The supernatant from day 6 (144 h) postinfection was transferred to a
new monolayer of (3  106 cells) Vero E6 cells, and fresh DMEM con-
taining 2% FBS and 0.01% PEST was added 1:1. The cells were kept for
additional 7 days before the supernatant was transferred to a new mono-
layer of fresh cells. This procedure was repeated for three passages. After
the last passage, the cells were harvested by the addition of TRIzol accord-
ing to the manufacturer’s instructions. Three independent experiments
were performed.
Inactivation of EBOV in whole blood was performed by spiking
healthy donor blood (whole blood) (100 l) with 2  106 infectious
EBOVparticles (100l). Spiked bloodwasmixed 1:1withMPLBbuffer or
DMEM. The mixtures were incubated for 20 min at room temperature,
and 20 l was diluted 1:1,000 in DMEM containing 2% FBS and 0.01%
PEST in order to dilute the toxic compounds in the MPLB buffer. The
solution was added to confluent Vero E6 cells. After 2 h of infection at
37°C, the cells were washed twice and incubated with DMEM containing
2% FBS and 0.01% PEST. At day 7 postinfection, the cells were harvested
by the addition of TRIzol. Three independent experiments were per-
formed.
For analysis of EBOV inactivation, the EBOV RNA expression level
was evaluated. NA extraction was performed by adding chloroform to the
TRIzol-lysed cells (ratio, 1:5) followed by incubation for 3 min at room
temperature and centrifugation at 12,000 g for 15min at 4°C. RNAwas
extracted from the aqueous phase using the QIAamp viral RNA minikit
(Qiagen, Hilden, Germany) according to the manufacturer’s recommen-
dations. The expression of EBOVRNAwas evaluated in duplicateswith an
in-house modified version of an assay published by Gibb et al. (20). The
TaqMan fast virus 1-step master mix and the StepOnePlus real-time PCR
system (Thermo Fisher Scientific, Inc., Waltham, MA, United States)
were used. Human beta-actin mRNA was evaluated using a commercial
endogenous control gene expression assay (ThermoFisher Scientific, Inc.,
Waltham,MA, United States). The EBOV RNA levels were normalized to
beta-actin levels and presented as the relative expression compared to
normalized data obtained from mock-treated cells.
Preparation of blood collection vacuum tubes for rapid bedside in-
activation. MPLB buffer was added to ordinary blood collection vacu-
tainer K2 EDTA tubes (4 ml) (Becton Dickinson, Franklin Lakes, NJ,
United States) using a 25G 1 needle (BectonDickinson, Franklin Lakes,
NJ, United States) and a 3-ml Luer Lok syringe (BectonDickinson, Frank-
lin Lakes, NJ, United States). The ratio of MPLB buffer to EDTA-blood
was 1:1. Repeated experiments showed that the addition of 1.6 ml of
MPLB buffer to a 4-ml vacutainer EDTA tube resulted in an automatic
collection of 1.6 ml of blood due to the remaining vacuum in these tubes.
After intravenous blood collection using a butterfly needle with small-
bore extension tubing, the tube contents were mixed by flipping the tube
5 to 10 times by hand. The tubes were disinfected on the outside using 1%
Virkon (Wilmington, DE, United States) or 70% ethanol and were ready
to be spiked with the EBOV or used directly for NA extraction.
EBOV RNA purification and stability experiments. Healthy donor
blood was collected at the Statens Serum Institut (SSI) (Copenhagen,
Denmark) using the blood collection vacuum tubes containing theMPLB
buffer and spiked with a solution of the gamma-irradiated and freeze-
dried EBOV standard preparation for diagnostic purposes (ENIVD) pre-
pared from the recent outbreak in Guéckédou/Guinea. The freeze-dried
EBOV standard preparation was resolved in 100l of nuclease-free water
and diluted 1:10, resulting in a stock solution containing 2  106 cop-
ies/ml (genome copies). Aliquots of 50 l were prepared in tubes with
gaskets and stored at 80°C. Tenfold dilutions were prepared from the
EBOV standard stock solution in nuclease-free water. Then, 50l of each
dilutionwas spiked into 2ml ofMPLB buffer-inactivated blood. Total NA
was extracted from 1 ml of MPLB buffer-inactivated blood using the
Magna Pure 96 DNA and viral NA large-volume kit and aMagna Pure 96
robot (Roche Diagnostics A/S, Risch-Rotkreuz, Switzerland). The manu-
facturer’s instructions were followed except that the first step in the pro-
tocol (addition of MPLB buffer) was omitted. The samples were eluted in
50 l of elution buffer. A slightly modified version of the QIAamp viral
RNA minikit protocol was also used. Briefly, the first four steps in the
QIAamp viral RNA minikit spin protocol were omitted, and the RNA
extraction protocol was followed from step 5 by adding 560 l of ethanol
(96 to 99%) to 700 l of the MPLB buffer-inactivated spiked sample.
Here, the spin protocol was followed according to the manufacturer’s
instructions. The samples were eluted in 50 l of AVE elution buffer.
The expression of EBOV RNA was evaluated in duplicates with an
in-housemodified version of an assay published byWeidmann et al. (21).
The SensiFast probeNo-Rox one-step kit (Meridian Bioscience, Inc., Cin-
cinnati, OH, United States) and the Mx3005P thermal cycler (Stratagene,
CA, United States) were used according to the manufacturers’ instruc-
tions. The commercial RealStar filovirus screen RT-PCR master mix
(AltonaDiagnostics,Hamburg,Germany) (22)was also used according to
the manufacturer’s instructions. Purified EBOV RNA was included in
every RT-PCR as a positive control to evaluate the integrity of the assay.
Nuclease-free water was used in all experiments as a negative control. In
the RealStar filovirus screenRT-PCR assay, the internal control was added
to the reaction mixture to assess RT-PCR inhibition.
EBOV-positive clinical blood samples were obtained from a Norwe-
gian patient diagnosed with EVD in Sierra Leone and repatriated to Nor-
way for treatment at the clinical BSL-4 isolation unit at Oslo University
Hospital, Ullevål, Norway. Blood was collected using either the MPLB
buffer-containing blood collection vacuumEDTA tubes or normal EDTA
tubes without MPLB buffer. Total NA was isolated using Magna Pure LC
(Roche Diagnostics A/S, Risch-Rotkreuz, Switzerland) with an elution
volume of 100 l. For comparison, EBOV RNA was also extracted with
the QIAamp viral RNA minikit using the automated QIAcube (Qiagen,
Hilden, Germany). The expression of EBOV RNA was evaluated with an
in-house modified version of an assay published by Huang et al. (23). In
this assay, the sequences for the forward primer and probe were slightly
modified to account for mismatches in the recent EBOV outbreak strain
Rosenstierne et al.
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(Enp-F: 5=-GCAGAGCAAGGACTGATACA-3= and Enp-P: FAM-5=-CAA
CAGCTTGGCAATCAGTAGGACA-3=-BHQ1). Then, 2 l of RNA was
analyzed in a 25-l reaction using 500-nM primers and a 200-nM probe.
The RT-PCR was performed with the one-step RT-PCR kit (Qiagen,
Hilden, Germany) using the RotorGene cycler system (Qiagen, Hilden,
Germany). The viral load in the clinical samples was estimated from a
standard curve of the inactivated EBOV standard preparation for diag-
nostic purposes (i.e., ENIVD).
RESULTS
Inactivation of EBOVusingMPLBbuffer.Weevaluatedwhether
MPLB buffer inactivated EBOV.Under BSL-4 conditions, 2 106
infectious EBOVparticles were either treatedwithMPLBbuffer or
mock treated with DMEM, filtered, and used to infect Vero E6
cells. At 24, 48, 144, and 336 h postinfection, EBOV and beta-actin
RNA expressions were analyzed by RT-PCR. Viral EBOV RNA
levels were normalized to beta-actin RNA levels and presented as
the relative expression compared to levels obtained with mock-
treated virus at 24 and 48 h postinfection (Fig. 1A). The presence
of EBOV particles was also analyzed by staining the cells 24 and 48
h postinfection with specific antibodies targeting the EBOV VP40
and GP (Fig. 1B).
At 24 and 48 h postinfection, the viral EBOV RNA level in the
cells infected with MPLB buffer-treated EBOV was 4-log units
lower than in the cells infectedwithmock-treated EBOV (Fig. 1A).
The relative expression of EBOVRNA in theMPLB buffer-treated
EBOV-infected cells decreased to undetectable level (Cq 40) at
later postinfection time points. In contrast, the relative EBOV
RNA expression in the mock-treated EBOV-infected cells in-
creased by more than 5-log units postinfection (Fig. 1A). EBOV-
specific staining of the cells at 24 h (data not shown) and 48 h (Fig.
1B) postinfection did not show any presence of EBOV in the
MPLB buffer-treated EBOV-infected cells, in contrast to the
mock-treated EBOV-infected cells, where EBOV could easily be
detected (Fig. 1B).
To investigate if the infectivity changed over a longer period of
time, the supernatant from day 6 (144 h) postinfection was pas-
saged onto fresh Vero E6 cells 3 consecutive times with 7-day
intervals. To demonstrate the sensitivity of the assay, an experi-
mentwas included inwhich only 5 infectious EBOVparticles were
mock treated with DMEM, filtered, used to infect Vero E6 cells,
and passaged 3 times as described above. The cell monolayers
from all of the passages were harvested and analyzed for EBOV
and beta-actin RNA expression by RT-PCR. The viral EBOVRNA
levels were normalized to beta-actin RNA levels and presented as
the relative expression compared to levels obtained with mock-
treated virus 24 h postinfection (Fig. 1C). The relative expression
of the EBOV RNA in the MPLB buffer-treated EBOV-infected
cells did not increase over time (3 passages) (Fig. 1C).We detected
as low as 5 virus particles using filtration and passaging, which
demonstrates the sensitivity of this assay to detect live virus. These
results clearly demonstrate that the MPLB buffer inactivates
EBOV and that MPLB buffer-treated EBOV does not replicate.
Furthermore, the inactivation efficiency in blood was evalu-
ated by spiking whole blood with 2 106 infectious EBOV parti-
cles. The spiked blood samples were eithermock treated or treated
with MPLB buffer and used to infect Vero E6 cells. The MPLB
buffer is very toxic and, in the previous experiments, Ambicon
X100 filters were used to wash away the toxic compounds. How-
ever, Ambicon X100 filters could not be used in this experiment
due to clogging of the filter by cell debris from the blood sample.
Instead, the MPLB-inactivated blood sample was diluted 1:1,000
in order to reduce the toxic concentration. At day 7 postinfection,
EBOVandbeta-actinRNAexpressionswere analyzed byRT-PCR.
The viral EBOV RNA levels were normalized to beta-actin RNA
levels and compared to levels obtained with mock-treated virus
(Fig. 1D).
At 7 days postinfection, the viral EBOV RNA level in the cells
infected withMPLB buffer-treated EBOV-spiked blood was 7-log
units lower than cells infected with mock-treated EBOV-spiked
blood (Fig. 1D). These results demonstrate that MPLB buffer in-
activates EBOV-spiked whole blood.
Preparation and test of stability of blood collection vacuum
tubes for rapid bedside inactivation. Bedside inactivation tubes
were prepared by injecting MPLB buffer directly into vacutainer
EDTA tubes using a thin needle and syringe (Fig. 2A to C). The
vacuum in the tube has to be preserved to maintain the ability for
a direct drain of blood from the patient into the tube containing
theMPLB buffer (Fig. 2D). After blood collection using a butterfly
needle with small-bore extension tubing, the tube contents were
mixed by flipping the tube 5 to 10 times by hand. The outside
surface of the tubes was disinfected using 1% Virkon or 70% eth-
anol, and the samples were ready for NA extraction.
To evaluate the stability of the blood collection vacuum tubes
containing theMPLB buffer, tubes were prepared and stored for 1
to 16 weeks under different temperatures (5°C, 25°C, and 37°C).
After storage, intravenous blood was collected as described above
and spiked with an inactivated EBOV standard preparation, re-
sulting in a final concentration of 5  103 copies/ml. RNA was
extracted using the Magna Pure 96 robot, and EBOV RNA was
analyzed using the in-house modified EBOV RT-PCR assay (21)
and the RealStar filovirus screen RT-PCR assay. The blood collec-
tion vacuum tubes containing the MPLB buffer maintained the
residual vacuum for at least 16 weeks, and no adverse effect on
EBOV RT-PCR detection was observed after sample collection
(data not shown).
Analysis of RNA extraction methods. MPLB buffer is pro-
duced for automated Magna Pure nucleic acid extraction using
the Magna Pure robot. Therefore, we investigated whether sam-
ples treated with the MPLB buffer could be extracted manually
with the QIAamp viral RNA minikit. Intravenous blood was col-
lected using the MPLB buffer-containing blood collection tubes.
The MPLB buffer-treated samples were spiked with a 10-fold di-
lution series of the inactivated EBOV standard, resulting in a final
EBOV sample concentration ranging between 50 and 50,000 cop-
ies/ml. RNAwas extracted in a parallel workflow using theMagna
Pure 96 robot, and a modified version of the QIAamp viral RNA
minikit. EBOV RNA was analyzed using the modified in-house
EBOV RT-PCR assay (21) and the RealStar filovirus screen RT-
PCR assay (Fig. 3).
Decreased RNA levels was observed for blood samples purified
with the QIAamp viral RNA minikit compared to Magna Pure
purified samples (Fig. 3). If RNA extraction was not performed
immediately or within 2 h after blood collection, then extraction
using the QIAamp viral RNA minikit was very difficult due to
clogging of the purification columns, resulting in a reduced RNA
yield. These results show thatMPLB buffer-treated samples can be
purified manually using the QIAamp viral RNA minikit.
Differences in sensitivity were observed between the in-house
EBOV RT-PCR assay and the RealStar filovirus screen RT-PCR
assay (Fig. 3). The sensitivity of the RealStar filovirus screen RT-
Bedside Inactivation of Ebola Virus
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PCR assay (Fig. 3) was lower than that of the in-house EBOV
RT-PCR assay (Fig. 3A). The in-house EBOV RT-PCR assay de-
tected EBOV RNA in blood containing 50 copies/ml of EBOV
(Fig. 3), whereas the RealStar filovirus screen RT-PCR assay had a
cutoff of 5,000 copies/ml of EBOV (Fig. 3). These results show that
the commercial RealStar filovirus screen RT-PCR assay was less
sensitive for blood samples than the in-house modified EBOV
RT-PCR assay in our setting.
Stability of EBOVRNA after inactivationwithMPLB buffer.
To analyze the stability of the EBOV RNA in the MPLB buffer,
intravenous blood was collected using the MPLB buffer-contain-
ing blood collection tubes. TheMPLBbuffer-treated sampleswere
spiked with the EBOV standard preparation, resulting in a final
EBOV sample concentration of 5  103 copies/ml. The spiked
samples were stored for 1 to 28 days at 5°C, 25°C, and 37°C. After
storage, RNA was extracted using the Magna Pure 96 robot and
FIG 1 Effect of MPLB buffer on EBOV infectivity. Two million cultured infectious EBOV particles were treated with MPLB buffer or DMEM (mock-treated)
(1:1) and used to infect Vero E6 cells. (A) The cells were harvested at 24, 48, 144, and 336 h postinfection and analyzed for EBOV viral RNA. The EBOV viral RNA
levels were normalized to the beta-actin RNA levels (internal control) and presented as the relative expression to levels obtained with mock-treated virus at 24 h
postinfection. Black solid lines represents relative EBOV RNA levels from mock-treated EBOV-infected cells; dotted lines represents relative EBOV RNA levels
fromMPLB buffer-treated EBOV-infected cells. The mean the standard error of the mean (SEM) from the 3 independent experiments is shown. (B) The cells
were fixed at 48 h postinfection and stained for EBOV using specific in-house antibodies targeting the EBOVVP40 and GP. (C) Supernatant frommock-treated
EBOV andMPLB buffer-treated EBOV-infected cells were passed every 7 days in Vero E6 cells for 3 passages. The EBOV viral RNA levels were normalized to the
beta-actin RNA levels (internal control) and presented as the relative expression to levels obtained withmock-treated virus at 24 h postinfection. Black solid lines
represent relative EBOV RNA levels frommock-treated EBOV-infected cells (2 106 infectious EBOV particles); solid gray lines represent relative EBOV RNA
levels from mock-treated EBOV-infected cells (5 infectious EBOV particles). The dotted lines represent relative EBOV RNA levels from MPLB buffer-treated
EBOV-infected cells (2  106 EBOV particles). The mean  SEM from the 3 independent experiments is shown. (D) Whole blood was spiked with 2  106
infectious EBOV particles, treated with MPLB buffer or DMEM (mock-treated) (1:1), diluted 1:1,000, and used to infect Vero E6 cells. The cells were harvested
at day 7 postinfection and analyzed for EBOV viral RNA. The EBOV viral RNA levels were normalized to the beta-actin RNA levels (internal control) and
presented as the relative expression to levels obtained with mock-treated virus. The mean SEM from the 3 independent experiments is shown.
Rosenstierne et al.
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the QIAamp viral RNA minikit. EBOV RNA was analyzed using
the in-house EBOV RT-PCR assay (21) (Fig. 4).
EBOV RNA was stable in the MPLB buffer-treated blood for
the entire 28-day test period independent of the storage tempera-
ture (Fig. 4). Small variations in EBOV RNA levels were observed
for samples stored at 25°C and 37°C when the RNA was extracted
with the Magna Pure extraction method (Fig. 4). In contrast,
EBOV RNA extraction from these samples using the QIAamp
RNAmethod was very difficult due to clogging of the purification
columns; hence, no EBOVRNA could be detected after 24 to 48 h.
Clogging of the purification columns was not observed when the
blood samples were stored at 5°C (Fig. 4). These results show that
RNA is preserved inMPLB buffer for at least 5 weeks independent
of the storage temperature. However, the QIAamp RNA extrac-
FIG 2 Preparation of blood collection vacuum tubes containingMPLB buffer. (A)Materials required for the preparation of blood collection tubes, including the
BDvacutainerK2EDTA tubes (4ml), theMagnaPure LCDNA isolation kit I lysis/binding buffer refill, the 3-mlBDLuer Lok syringe, and theBD25G 1needle.
(B, C) A total of 1.6 ml of MPLB buffer is added to the vacutainer EDTA tube by puncturing the cap of the tube. The cap of the tube should not be removed,
because the vacuum in the tube has to be preserved for subsequent blood collection. (D) Using the remaining vacuum in the vacutainer tube, 1.6 ml of
intravenous blood is automatically collected using a butterfly needle and directly inactivated by the presence of the MPLB buffer in the tube.
Bedside Inactivation of Ebola Virus
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tion method is dependent on the storage temperature of the
MPLB buffer-treated blood samples.
Stability of EBOVRNAusing bedside inactivation of EBOV-
positive patient samples. In October 2014, a Norwegian physi-
cian working in Sierra Leone who tested positive for EBOV was
transported to Oslo University Hospital, Ullevål, Norway, for
treatment. For daily monitoring of the EBOV viral load, the pa-
tient’s blood was inactivated within the BSL-4 isolation unit using
MPLB buffer prior to shipping to the Department of Microbiol-
ogy at Oslo University Hospital and the Norwegian Institute of
Public Health for analysis. To evaluate the effectiveness of bedside
inactivation, blood inactivated in MPLB buffer-containing vac-
uum tubes (8 ml) was compared to MPLB buffer bench-treated
blood. For this analysis, 4 ml of blood was mixed with 3 ml of
MPLB buffer. Total RNA was extracted using the Magna Pure
system and an automated QIAamp viral RNA extraction system
using the QIAcube. EBOV was quantified using a standard curve
of the EBOV standard preparation and the EBOV RT-PCR assay
(23) (Table 1).
Similar EBOV RNA levels were observed between the bedside-
inactivated and the bench-inactivated samples and between the
two RNA extraction methods (Table 1). These results demon-
strate the real-life use ofMPLB buffer-containing blood collection
tubes as an easy bedside inactivation procedure for EBOV-posi-
tive clinical samples.
DISCUSSION
Rapid bedside inactivation of EBOV is crucial for the safety of
medical and technical staff, risk containment, and sample trans-
port. Additionally, bedside inactivation removes the need for
sample handling under high-containment conditions, which fa-
cilitates high-throughput testing and rapid diagnosis of the dis-
ease. In this study, we demonstrated inactivation of EBOV by the
commercially available MPLB buffer used for NA extraction.
EBOV inactivation was analyzed by examining viral replication in
MPLB buffer-treated or mock-treated EBOV-infected cells at dif-
ferent postinfection time points (up to three passages). Using this
assay, we could detect as low as five infectious EBOV particles.We
detected EBOV replication in cells infected with mock-treated
EBOV but not in cells infected with MPLB buffer-treated EBOV,
which clearly demonstrated that theMPLB buffer efficiently inac-
tivated EBOV. We used two million infectious virus particles of
cultured virus, which corresponded to a Cq value of about 15 in
our RT-PCR settings. This corresponded to a higher concentra-
tion level of the EBOV compared to the most reported cases from
the 2014 outbreak (24, 25).
The use of commercially available NA extraction reagents for
EBOV inactivation is well known (13), and these reagents are cur-
rently used (15). A recent report by Smither et al., in 2015, showed
that the frequently used AVL buffer alone did not inactivate
EBOV. EBOV-spiked mouse blood treated with AVL buffer
needed to be combined with either heat or ethanol to ensure com-
plete EBOV inactivation over the time of three passages (26). We
showed that the MPLB buffer inactivated EBOV over the time of
three passages without the need for additional treatment. How-
ever, these experiments were performed on EBOV cell cultures
and not spiked blood samples. We showed a 7-log reduction in
EBOV RNA levels for MPLB buffer-treated spiked blood samples
compared to mock-treated blood samples at 7 days postinfection;
however, the viability of EBOV in spiked blood samples was not
tested over time. Nevertheless, the results after the 7 days postin-
fection compared to the cultured virus are comparable.
There is a potential that the MPLB buffer does not have the
same effectiveness on inactivation of EBOV in blood as it has on
EBOV in cell culture. MPLB buffer is very toxic to cells; therefore,
a filtration step was used prior to the addition to Vero E6 cells.
However, filtration could not be used for the EBOV-spiked blood
samples due to clogging of the filters, so a 1:1,000 dilution of the
MPLB buffer-treated or mock-treated blood samples was used
instead. Using this high dilution of the spiked blood samples, we
might have lost the sensitivity of the assay, and the lack of passage
over time could introduce the potential for small residues of in-
fectious EBOV to remain. However, since the results from 7 days
postinfection are comparable between the spiked blood and the
cultured virus, it may indicate that the MPLB treatment will inac-
tivate Ebola virus even in the spiked blood samples. Nevertheless,
one should have it in mind that the inactivation is dependent not
only on thematrix of samples but also on the concentration of the
virus, and this concentration may differ between individuals.
However, these data demonstrate that using vacuumMPLB tubes
FIG 3 Analysis of RNA extraction methods. Intravenous blood was collected
using MPLB buffer blood collection tubes and spiked with a 10-fold dilution
series of the inactivated EBOV standard (std) preparation. RNA was extracted
in a parallel workflow using the Magna Pure 96 robot and the QIAamp viral
RNA minikit. EBOV RNA was analyzed using the in-house EBOV RT-PCR
assay and the RealStar filovirus screen RT-PCR assay. ThemeanCq standard
deviation (SD) of replicates is shown (n 8).
FIG 4 Stability of EBOV RNA after inactivation with MPLB buffer. Intrave-
nous blood was collected using MPLB buffer blood collection tubes. The col-
lected samples were spiked with the inactivated EBOV standard (final concen-
tration, 5 103 copies/ml) and stored at 5°C, 25°C, and 37°C for 0 to 28 days.
RNAwas extracted in parallel usingMagna Pure RNA extraction andQIAamp
viral RNA extraction. EBOV RNA was analyzed using the in-house EBOV
RT-PCR assay. Purified EBOV RNA was included in every RT-PCR as a posi-
tive control (Pos ctrl), and nuclease-free water was used in all experiments as a
negative control (Neg ctrl). The mean Cq SD of duplicates is shown.
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increases the biosafety aspects of the handling of samples signifi-
cantly.
The MPLB buffer contains 20 to 25% Triton X-100 and 30 to
50%guanidinium thiocyanate (GITC) (27), whereas theAVLbuf-
fer contains 50 to 70%GITC (28). TritonX-100 has been shown to
inactivate a wide range of enveloped viruses (29), and the combi-
nation of Triton X-100 and GITC in theMPLB buffer might indi-
cate that the MPLB buffer is more efficient than the AVL buffer.
TheMPLB buffer has been shown to inactivate Vaccinia virus and
Cowpox virus (18). This, combinedwith the results from the pres-
ent study, indicates that other viruses will be inactivated byMPLB
buffer as well, including risk group 4 pathogens such as Lassa
virus, Marburg virus, and Crimean Congo hemorrhagic fever vi-
rus. However, this speculation is not within the scope of this study
and requires further investigation.
MPLB buffer is produced for automated Magna Pure NA ex-
traction using aMagna Pure robot. This NA extraction system is a
high-throughput machine that can perform 96 NA extractions in
less than 1 h. However, this machine is not always available in
resource-poor settings, field laboratories or high-containment fa-
cilities. We showed that EBOV RNA could be extracted from
MPLB buffer-inactivated blood samples using the manual
QIAamp viral RNA minikit. However, RNA extraction using the
QIAamp viral RNA minikit is dependent on the time after blood
collection and the storage temperature. Often, there is a time span
between sample collection and laboratory analysis. Blood samples
stored at 25°C or 37°C could easily be extracted using the Magna
Pure RNA extraction system; however, RNA extraction using the
QIAamp viral RNA extraction kit was very difficult due to clog-
ging of the purification columns. This phenomenon was not ob-
served for blood samples stored at 5°C, where EBOV RNA could
be detected in the samples 28 days after blood collection using
either extraction method without difficulty or loss of material.
The current WHO guidelines recommend a storage temperature
between 0 and 5°C to preserve EBOV RNA in EDTA-blood sam-
ples (3), and rapid degradation of EBOV RNA has been observed
when samples are stored at room temperature compared to 4°C
(17). However, our results demonstrate that MPLB buffer pre-
serves the EBOV RNA even when the samples are stored at 25 to
37°C. This observation simplifies sample collection, because it
eliminates the need for cooling (e.g., during transport and ship-
ment). However, the consequence of this stability is that MPLB
buffer-treated blood samples need to be processed by the Magna
Pure RNA extraction system.
We also show that the commercial WHO-approved RealStar
filovirus screen RT-PCR assay (22, 30) was less sensitive than a
modified in-house EBOV RT-PCR assay (21). This difference
might reflect incompatibility between the RealStar filovirus screen
RT-PCR assay and the RNA extraction methods used in our ex-
periments. The RealStar filovirus screen RT-PCR assay was opti-
mized for the QIAamp viral RNA minikit (22, 30), whereas our
QIAamp viral RNA extractionmethod is amodified version of the
original protocol due to the use of MPLB buffer. This discrepancy
could explain the lower sensitivity of the RealStar filovirus screen
RT-PCR assay in our experiments. Very few reports have been
published regarding the performance of commercial EBOV RT-
PCR assays, but, in a recent communication, a similar low sensi-
tivity of the RealStar filovirus screen RT-PCR assay (31) was re-
ported. These results indicate the necessity for confirmatory
EBOV RT-PCR analysis when analyzing clinical samples sus-
pected to be positive for EBOV (3).
A bedside inactivation method is easily obtained by adding
MPLB buffer directly into vacutainer EDTA-blood collection
tubes. However, a few safety precautions are important when es-
tablishing procedures for the use of theseMPLBbuffer-containing
tubes in a clinical setting. First, it is essential to prevent backflowof
theMPLB buffer from the collection tube into the vein. Therefore,
we recommend that sample collection always be performedwith a
butterfly needle with small-bore extension tubing, with the pa-
tient’s arm in a downward position and the collection tube posi-
tioned lower than the butterfly needle. Second, if MPLB buffer is
spilled, the contaminated surface must never be disinfected with
chloramine or sodium hypochlorite (the active ingredients in
bleach) as the first cleaning step, because this action may lead to
the formation of toxic cyanide. Instead, first wipe up the spilled
MPLB buffer, clean the surface with 70% ethanol, then clean with
water, and then use chloramine or sodiumhypochlorite according
the manufacturers’ recommendations.
This bedside inactivation method was applied in Norway on a
case patient who had been diagnosed with EVD in Sierra Leone
and subsequently been repatriated for treatment. The Oslo Uni-
versity hospital has a small BSL-4 laboratory in connection with
the clinical BSL-4 isolation unit, but this laboratory lacks the fa-
cilities for NA extraction andmolecular diagnostics. The inactiva-
tion of EBOV using MPLB buffer-containing blood collection
tubes eliminated the need for the shipment of samples to BSL-4
laboratories in other countries for analysis, thereby facilitating
rapid and daily monitoring of the patient’s EBOV viral load in the
primary laboratory, NA-based differential diagnostics of other
pathogens, and rapid sharing of inactivated material between lab-
oratories. However, MPLB buffer will have a negative impact on
biochemical and serology tests; therefore, these tests will still re-
quire BSL-4 handling.
In summary, we present an easy, efficient, and robust bed-
side inactivation method for NA tests by adding MPLB buffer
directly into ordinary vacuum blood collection tubes. These
inactivation tubes can be prepared and stored for at least 5
months independent of the storage temperature without losing
the vacuum and function. We suggest using this bedside inac-
tivation method for the collection of blood from patients sus-
pected of EVD or other BSL-4 viruses, for the safe transport of
samples, and for safe routine NA testing without the need for
BSL-4 facilities. In the case of an outbreak situation, these tubes
can easily be prepared and transported to different locations;
TABLE 1 EBOV viral load from an EBOV-positive patient
Sample name Collection date Inactivation method Extraction method Extraction volume (l) Cq value Viral load (copies/ml)
FHI0001 8 October 2014 Bedside inactivation Magna Pure 100 27.5 847,000
Qiacube 100 26.9 768,000
FHI0005 10 October 2014 Bench inactivation Magna Pure 100 27.7 734,500
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however, this has not been tested. It would be desirable to have
the addition of MPLB buffer to vacuum EDTA-blood collec-
tion tubes commercialized, and manual preparation would
therefore only be a solution in case of a sudden emergency.
Commercialization would also remove the risk of sudden
changes in buffer content or concentrations that might influ-
ence the inactivation efficiency of the MPLB buffer.
ACKNOWLEDGMENTS
We thank the European Network for Diagnostics of Imported Viral Dis-
eases (ENIVD), the Bernhard-Nocht-Institut (BNI) in Hamburg, and the
University of Marburg and Robert Kock-Institut in Berlin, Germany, for
providing the EBOV standard preparation for diagnostic purposes. We
also thank Manfred Weidman, University of Stirling, Scotland, for pro-
viding us with additional vials of the EBOV standard preparation. We
thank Solvej Kolbjørn Jensen and Pundharika Barkved for technical assis-
tance, Mette Sannes for handling the clinical samples, and Kirsti Jakobsen
for managing the virological monitoring of patient samples.
This project is part of the EbolaMoDRAD consortium, which has re-
ceived funding from the InnovativeMedicine Initiative 2 Joint Undertak-
ing under grant agreement 115843. this joint undertaking receives sup-
port from the European Union Horizon 2020 research and innovation
program and EFPIA.
FUNDING INFORMATION
This work, including the efforts of Maiken Worsøe Rosenstierne, Helen
Karlberg, AliMirazimi, andAnders Fomsgaard, was funded by Innovative
Medicine Initiative 2 (115843).
This project is part of the EbolaMoDRAD consortium, which has received
funding from the Innovative Medicine Initiative 2 Joint Undertaking un-
der grant agreement 115843. This joint undertaking receives support from
the European Union Horizon 2020 research and innovation programme
and EFPIA.
REFERENCES
1. World Health Organization. 2016. Ebola situation report, 30 March
2016. http://apps.who.int/iris/bitstream/10665/204714/1/ebolasitrep_30
mar2016_eng.pdf?ua1&ua1.
2. Wölfel R, Stoecker K, Fleischmann E, Gramsamer B, Wagner M,
Molkenthin P, Di Caro A, Günther S, Ibrahim S, Genzel GH, Ozin-
Hofsäss AJ, Formenty P, Zöller L. 2015. Mobile diagnostics in outbreak
response, not only for Ebola: a blueprint for a modular and robust field
laboratory. Euro Surveill 20:pii30055. http://www.eurosurveillance.org
/ViewArticle.aspx?ArticleId21291.
3. World Health Organization. 2014. Laboratory diagnosis of Ebola virus
disease, 19 September 2014. http://apps.who.int/iris/bitstream/10665/134
009/1/WHO_EVD_GUIDANCE_LAB_14.1_eng.pdf.
4. World Health Organization. 2004. Laboratory biosafety manual (3rd ed).
http://www.who.int/csr/resources/publications/biosafety/Biosafety7.pdf.
5. World Health Organization. 2014. How to safely ship human blood
samples from suspected Ebola cases within a country by road, rail, and sea.
http://apps.who.int/iris/bitstream/10665/137549/1/WHO_EVD
_Guidance_Lab_14.3_eng.pdf.
6. World Health Organization. 2014. How to safely collect blood samples
from persons suspected to be infected with highly infectious blood-borne
pathogens (e.g., Ebola). http://who.int/csr/resources/publications/ebola
/blood-collect-en.pdf.
7. World Health Organization. 2015. Ebola situation report, 19 August
2015. http://apps.who.int/ebola/current-situation/ebola-situation-report
-19-august-2015.
8. Elliott LH, McCormick JB, Johnson KM. 1982. Inactivation of Lassa,
Marburg, and Ebola viruses by gamma irradiation. J Clin Microbiol 16:
704–708.
9. Sagripanti J-L, Lytle CD. 2011. Sensitivity to ultraviolet radiation of
Lassa, Vaccinia, and Ebola viruses dried on surfaces. Arch Virol 156:489–
494. http://dx.doi.org/10.1007/s00705-010-0847-1.
10. Chepurnov AA, Bakulina LF, Dadaeva AA, Ustinova EN, Chepurnova
TS, Baker JR, Jr. 2003. Inactivation of Ebola virus with a surfactant
nanoemulsion. Acta Trop 87:315–320. http://dx.doi.org/10.1016/S0001
-706X(03)00120-7.
11. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Viard M, Aitichou
M, Chi X, Ibrahim S, Blumenthal R, Raviv Y, Bavari S, Aman MJ. 2007.
Ebola virus inactivation with preservation of antigenic and structural in-
tegrity by a photoinducible alkylating agent. J Infect Dis 196:S276–S283.
http://dx.doi.org/10.1086/520605.
12. Mitchell SW, McCormick JB. 1984. Physicochemical inactivation of
Lassa, Ebola, and Marburg viruses and effect on clinical laboratory analy-
ses. J Clin Microbiol 20:486–489.
13. Blow JA, Dohm DJ, Negley DL, Mores CN. 2004. Virus inactivation by
nucleic acid extraction reagents. J Virol Methods 119:195–198. http://dx
.doi.org/10.1016/j.jviromet.2004.03.015.
14. Lau R, Wang A, Chong-kit A, Ralevski F, Boggild AK. 2015. Evaluation
of Ebola virus inactivation procedures for Plasmodium falciparummalaria
diagnostics: J Clin Microbiol 53:1387–1390.
15. Gire SK, Goba A, Andersen KG, Sealfon RSG, Park DJ, Kanneh L, Jalloh
S, Momoh M, Fullah M, Dudas G, Wohl S, Moses LM, Yozwiak NL,
Winnicki S, Matranga CB, Malboeuf CM, Qu J, Gladden AD, Schaffner
SF, Yang X, Jiang P-P, Nekoui M, Colubri A, Coomber MR, Fonnie M,
Moigboi A, Gbakie M, Kamara FK, Tucker V, Konuwa E, Saffa S, Sellu
J, Jalloh AA, Kovoma A, Koninga J, Mustapha I, Kargbo K, Foday M,
Yillah M, Kanneh F, Robert W, Massally JLB, Chapman SB, Bochicchio
J, Murphy C, Nusbaum C, Young S, Birren BW, Grant DS, Scheiffelin
JS, Lander ES, Happi C, Gevao SM, Gnirke A, Rambaut A, Garry RF,
Khan SH, Sabeti PC. 2014. Genomic surveillance elucidates Ebola virus
origin and transmission during the 2014 outbreak. Science 345:1369–
1372. http://dx.doi.org/10.1126/science.1259657.
16. Flint M, Goodman CH, Bearden S, Blau DM, Amman BR, Basile AJ,
Belser JA, Bergeron É Bowen MD, Brault AC, Campbell S, Chakrabarti
AK, Dodd KA, Erickson BR, Freeman MM, Gibbons A, Guerrero LW,
Klena JD, Lash RR, Lo MK, McMullan LK, Momoh G, Massally JL,
Goba A, Paddock CD, Priestley RA, Pyle M, Rayfield M, Russell BJ,
Salzer JS, Sanchez AJ, Schuh AJ, Sealy TK, Steinau M, Stoddard RA,
Taboy C, Turnsek M, Wang D, Zemtsova GE, Zivcec M, Spiropoulou
CF, Ströher U, Towner JS, Nichol ST, Bird BH. 2015. Ebola virus
diagnostics: theUSCenters forDiseaseControl andPrevention laboratory
in Sierra Leone, August 2014 to March 2015. J Infect Dis 212:S350–S358.
http://dx.doi.org/10.1093/infdis/jiv361.
17. Strecker T, Palyi B, Ellerbrok H, Jonckheere S, de Clerck H, Bore JA,
Gabriel M, Stoecker K, Eickmann M, van Herp M, Formenty P, Di Caro
A, Becker S. 2015. Field evaluation of capillary blood samples as a collec-
tion specimen for the rapid diagnosis of Ebola virus infection during an
outbreak emergency. Clin Infect Dis 61:669–675. http://dx.doi.org/10
.1093/cid/civ397.
18. Vinner L, Fomsgaard A. 2007. Inactivation of orthopoxvirus for diagnos-
tic PCR analysis. J Virol Methods 146:401–404. http://dx.doi.org/10.1016
/j.jviromet.2007.07.025.
19. Weidmann M, Sall AA, Manuguerra JC, Koivogur L, Adjami A, Traoré
FF, Hedlund KO, Lindegren G, Mirazimi A. 2011. Quantitative analysis
of particles, genomes and infectious particles in supernantants of hemor-
rhagic fever virus cell cultures. Virol J 8:81. http://dx.doi.org/10.1186
/1743-422X-8-81.
20. Gibb TR, Norwood DA, Jr, Woollen N, Henchal EA. 2001. Development
and evaluation of a fluorogenic 5=-nuclease assay to identify Marburg
virus. Mol Cell Probes 15:259–266. http://dx.doi.org/10.1006/mcpr.2001
.0369.
21. Weidmann M, Mühlberger E, Hufert FT. 2004. Rapid detection protocol
for filoviruses. J Clin Virol 30:94–99. http://dx.doi.org/10.1016/j.jcv.2003
.09.004.
22. Altona Diagnostics. 2014. RealStar filovirus screen RT-PCR kit 1.0 1-18.
http://www.altona-diagnostics.com/tl_files/website/downloads/RealStar
_Filovirus screen RT-PCR kit 10_CE_WEB_2014-08-29.pdf.
23. Huang Y, Wei H, Wang Y, Shi Z, Raoul H, Yuan Z. 2012. Rapid
detection of filoviruses by real-time TaqMan polymerase chain reac-
tion assays. Virol Sin 27:273–277. http://dx.doi.org/10.1007/s12250
-012-3252-y.
24. Yan T, Mu J, Qin E, Wang Y, Liu L, Wu D, Jia H, Li Z, Guo T, Wang
X, Qin Y, Li Y, Chen S, Zhang Y, Zhang J, Wu Y, Wang S. 2015. Clinical
characteristics of 154 patients suspected of having Ebola virus disease in
the Ebola holding center of Jui Government Hospital in Sierra Leone
Rosenstierne et al.
2528 jcm.asm.org October 2016 Volume 54 Number 10Journal of Clinical Microbiology
 o
n
 N
ovem
ber 2, 2016 by FO
LKHALSO
M
YNDIG
HETEN
http://jcm.asm.org/
D
ow
nloaded from
 
during the 2014 outbreak. Eur J Clin Microbiol Infect Dis 34:2089–2095.
http://dx.doi.org/10.1007/s10096-015-2457-z.
25. de La Vega MA, Caleo G, Audet J, Qiu X, Kozak RA, Brooks JI, Kern S,
Wolz A, Sprecher A, Greig J, Lokuge K, Kargbo DK, Kargbo B, Caro AD,
Grolla A, Kobasa D, Strong JE, Ippolito G, Herp MV, Kobinger GP. 2015.
Ebola viral load at diagnosis associates with patient outcome and outbreak
evolution. J Clin Invest 125:4421–4428. http://dx.doi.org/10.1172/JCI83162.
26. Smither SJ, Weller SA, Phelps A, Eastaugh L, Ngugi S, O’Brien LM,
Steward J, Lonsdale SG, Lever MS. 2015. Buffer AVL alone does not
inactivate Ebola virus in a representative clinical sample type. J Clin Mi-
crobiol 53:3148–3154. http://dx.doi.org/10.1128/JCM.01449-15.
27. Roche. 2014.MPLCDNA Isol.Kitl-Kysis/Bind.Buf.Refill safety data sheet.
https://pim-eservices.roche.com/SDS/DE/en/03246752001.
28. Qiagen. 2015. Buffer AVL: safety data sheet. http://www.qiagen.com/dk
/support/qa-qc-safety-data/safety-data-sheets/?a1&C002DK&C013
19073.
29. Roberts PL. 2008. Virus inactivation by solvent/detergent treatment using
Triton X-100 in a high purity factor VIII. Biologicals 36:330–335. http:
//dx.doi.org/10.1016/j.biologicals.2008.06.002.
30. World Health Organization. 2014. Emergency Quality Assessment Mecha-
nism for EVD IVDs: Public Report. http://www.who.int/diagnostics
_laboratory/procurement/141125_evd_public_report_altona_v1.pdf.
31. Janvier F, Gorbatch S, Queval L, Top J, Vigier C, Cotte J, Foissaud V.
2015. Difficulties of interpretation of Zaire Ebola Virus PCR results and
implication in the field. J Clin Virol 67:36–37. http://dx.doi.org/10.1016
/j.jcv.2015.04.001.
Bedside Inactivation of Ebola Virus
October 2016 Volume 54 Number 10 jcm.asm.org 2529Journal of Clinical Microbiology
 o
n
 N
ovem
ber 2, 2016 by FO
LKHALSO
M
YNDIG
HETEN
http://jcm.asm.org/
D
ow
nloaded from
 
